Takeda (TAK) and Vela Transport announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using Vela’s sailing cargo trimaran. Vela designed and will operate a fleet of new generation sailing cargo vessels, powered 100% by wind when at sea.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Protagonist Therapeutics initiated with an Outperform at Leerink
- Alkermes price target lowered to $43 from $45 at Needham
- Harmony Biosciences price target lowered to $48 from $49 at Needham
- Alkermes price target raised to $35 from $34 at JPMorgan
- Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating